Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could change how we prevent kidney rejection

NCT ID NCT01780844

Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called ASKP1240 in 149 people who received a new kidney. The goal was to see if it could prevent the body from rejecting the kidney as well as or better than current standard treatments. Participants received different combinations of drugs, and researchers measured how many had a rejection episode and how well the kidneys worked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

149 people

The number who actually took part.

Started

Mar 2013

Finished

Jan 2017

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is a recipient of a de novo kidney from a living or deceased donor Exclusion Criteria: * Subject has induction therapy, other than study-assigned basiliximab, planned as part of initial immunosuppressive regimen * Subject has previously received or is receiving an organ transplant other than a kidney * Subject will receive a solitary kidney from a deceased donor \< 5 years of age * Subject will receive a kidney with an anticipated cold ischemia time (CIT) of \> 30 hours * Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or DCD criteria is eligible for inclusion * Subject will receive an ABO incompatible donor kidney * Subject has a current calculated panel reactive antibody (cPRA) level \>50%

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplantation

Contacts and locations

Locations

  • Site US10001

    Dallas, Texas, 75246, United States

  • Site US10002

    Fort Worth, Texas, 76104, United States

  • Site US10003

    San Francisco, California, 94143, United States

  • Site US10004

    San Francisco, California, 94115, United States

  • Site US10005

    Madison, Wisconsin, 53792, United States

  • Site US10006

    Birmingham, Alabama, 35233, United States

  • Site US10007

    Atlanta, Georgia, 30322, United States

  • Site US10008

    Los Angeles, California, 90057, United States

  • Site US10009

    Cincinnati, Ohio, 45267, United States

  • Site US10010

    Chicago, Illinois, 60612, United States

  • Site US10012

    Charleston, South Carolina, 29425, United States

  • Site US10013

    Aurora, Colorado, 80045, United States

  • Site US10014

    Baltimore, Maryland, 21201, United States

  • Site US10015

    Lexington, Kentucky, 40536, United States

  • Site US10016

    Durham, North Carolina, 27710, United States

  • Site US10017

    Ann Arbor, Michigan, 48109, United States

  • Site US10018

    Chicago, Illinois, 60612, United States

  • Site US10019

    The Bronx, New York, 10467, United States

  • Site US10020

    Charlottesville, Virginia, 22908, United States

  • Site US10021

    Palo Alto, California, 94304, United States

  • Site US10022

    Livingston, New Jersey, 07039, United States

  • Site US10023

    New York, New York, 10065, United States

  • Site US10024

    Phoenix, Arizona, 85054, United States

  • Site US10025

    St Louis, Missouri, 63110, United States

  • Site US10026

    Greenville, North Carolina, 27834, United States

  • Site US10027

    Harrisburg, Pennsylvania, 17011, United States

  • Site US10028

    Memphis, Tennessee, 38104, United States

  • Site US10029

    Houston, Texas, 77030, United States

  • Site US10030

    San Diego, California, 92123, United States

  • Site US10031

    Buffalo, New York, 14215, United States

  • Site US10032

    Cleveland, Ohio, 44195, United States

  • Site US10033

    Salt Lake City, Utah, 84132, United States

  • Site US10034

    New York, New York, 10029, United States

  • Site US10035

    Nashville, Tennessee, 37232-4750, United States

  • Site US10036

    Chapel Hill, North Carolina, 27599, United States

  • Site US10037

    Chicago, Illinois, 60637, United States

  • Site US10038

    Pittsburgh, Pennsylvania, 15213, United States

  • Site US10040

    Cleveland, Ohio, 44106, United States

  • Site US10041

    Augusta, Georgia, 30912, United States

  • Site US10042

    Charlotte, North Carolina, 28203, United States

  • Site US10044

    Houston, Texas, 77030, United States

  • Site US10045

    New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.